Contact: +91-9711224068
  • Printed Journal
  • Indexed Journal
  • Refereed Journal
  • Peer Reviewed Journal
International Journal of Pharmacy and Pharmaceutical Science

Vol. 5, Issue 2, Part A (2023)

An observational study on AEFI in relation with COVID vaccine

Author(s):

Jes James, Joe Mariya Thankachan, Sneha Sony, L Panayappan and K Krishna Kumar

Abstract:

Background: Corona virus disease COVID-19, a respiratory disease which is caused by SARS-CoV 2 virus causing respiratory tract infections that can range from mild to lethal. Spreading of the disease is mainly by person contact to each other by air droplets infected persons exhalation. As a prevention for the disease should practice the sanitizing, wearing of mask, and practicing of social distancing. If affected with the disease should take or given with the symptomatic treatments, as a definite therapy was not yet established. Preventing of the disease should be considered in front step to stop the fast spreading, so as the first step world was urged for the development of the vaccines for the safety of public.

Aim: To assess the AEFI and identify the high risk population and also the occurrence of COVID after immunization in a tertiary care hospital.

Methods: The prospective observational study was conducted in a tertiary care hospital for a period of 6 months. A total of 217 participants who had taken the vaccination were included in the study. The details on age, gender, past medical history, adverse event after vaccination were collected. The data collected were analysed by using simple graphical method.

Results and Discussion: The study population included 217 participants who had taken COVID-19 vaccination. Participant responses were collected by telephonic interview and Google forms. The data was analysed using statistical methods. In this study, we found females were more prone to AEFI. Mean age group with more occurrence of AEFI was found in 19-60. Participants with comorbidities showed more incidence of adverse events than other individuals.

Conclusion: COVID virus disease 2019 is the respiratory disease which affects the people regardless of the age and gender. The adverse events after immunization was the major concern among public which reflected in the acceptance of vaccines. Along with that the studies regarding adverse event after vaccination and it's awareness will improve the percentage of vaccinated people. The adverse events following immunization are pain at injection site, fever, headache, fatigue, body pain, nausea and vomiting. Mild to moderate severity are observed among the affected ones. In rare cases serious AEFI like vaccine induced thrombocytopenia are also been reported. Even though we found high adverse event occurrence in middle aged and people with morbidity, there is need of further large population studies to confirm the high risk population.

Pages: 15-19  |  609 Views  106 Downloads


International Journal of Pharmacy and Pharmaceutical Science
How to cite this article:
Jes James, Joe Mariya Thankachan, Sneha Sony, L Panayappan and K Krishna Kumar. An observational study on AEFI in relation with COVID vaccine. Int. J. Pharm. Pharm. Sci. 2023;5(2):15-19. DOI: 10.33545/26647222.2023.v5.i2a.39